Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Tilray Inc is a drug manufacturers-specialty & generic business based in the US. Tilray shares (TLRY) are listed on the NASDAQ and all prices are listed in US Dollars. Tilray employs 1,800 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $5.79 |
|---|---|
| 52-week range | $5.70 - $67.00 |
| 50-day moving average | $8.68 |
| 200-day moving average | $13.08 |
| Wall St. target price | $9.35 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.73 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.79 from 2022-01-21
| 1 week (2022-01-13) | -15.72% |
|---|---|
| 1 month (2021-12-23) | -26.15% |
| 3 months (2021-10-20) | N/A |
| 6 months (2021-07-23) | -57.40% |
| 1 year (2021-01-22) | -67.87% |
|---|---|
| 2 years (2020-01-24) | -70.68% |
| 3 years (2019-01-24) | 73.96 |
| 5 years (2017-01-20) | N/A |
Valuing Tilray stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tilray's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tilray's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9 million.
The EBITDA is a measure of a Tilray's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $589.3 million |
|---|---|
| Gross profit TTM | $123.2 million |
| Return on assets TTM | -2.28% |
| Return on equity TTM | -8.5% |
| Profit margin | -46.67% |
| Book value | $9.57 |
| Market capitalisation | $2.7 billion |
TTM: trailing 12 months
We're not expecting Tilray to pay a dividend over the next 12 months.
Tilray's shares were split on 2 May 2021. This wouldn't directly have changed the overall worth of your Tilray shares – just the quantity. However, indirectly, the new INF% higher share price could have impacted the market appetite for Tilray shares which in turn could have impacted Tilray's share price.
Over the last 12 months, Tilray's shares have ranged in value from as little as $5.7 up to $67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tilray's is 2.6198. This would suggest that Tilray's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilray Brands Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Tilray, Inc.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
